The same sector — why does it make money for some and lose money for others? Everyone bought pharma, cheering when it rose, cursing the policy when it fell; yet a few years on, the account curves had diverged. The problem is rarely luck. Underneath the word pharma there is not one track but four businesses — blood products, traditional Chinese medicine, innovative drugs, generics — each eating from its own bowl, each playing its own script. Reading four scripts as one is the first source of losses.
Blood products live on licenses. Plasma-station permits sit with a few companies; new entrants cannot get in, so supply is rigid by nature. Rigidity is the valuable word: demand returns year after year, yet supply does not expand with price — no price high enough conjures a new permit. For a name like Shanghai RAAS, the value is not in a few extra points of this year’s profit; it is in the door that stays shut to everyone else. Demand follows medical usage, supply is pinned by the license — the anchor of this script is scarcity itself. Scarcity does not make it cheap; it makes the dips contested.
The ruler for traditional Chinese medicine measures the inventory cycle. The time-honored brand is the moat, but the goods in the channel do pile up: push inventory, digest it, push it again, round after round. One framework puts a number on it — the inventory cycle runs five years, a destocking round every three to five years, with positions built at the bottom, waiting for the start of the next round. The key to this business is not in the formula; it is in the rhythm. The rhythm is not read off a screen; it is read from where the goods in the channel stand.
Innovative drugs run on R&D spending. The spending is real, the output is slow, and the valuation the market grants keeps running out in front. One framework writes the script in four words: long-term overvaluation — avoid. A name like WuXi AppTec sits on this line: avoiding is not betting against the industry; it is declining to pay a premium.
Generics and APIs live on the centralized-procurement cycle. Policy presses prices down, margins thin out, and the industry fills with lament — and that is the one moment one framework opens its eyes: tracking only at extreme undervaluation. Extreme undervaluation is a threshold, not a slogan: until that level is reached, the lane stays off the list. The anchor of this script is where the price has fallen to, not the story the company tells.
First objection: it is all pharma — one policy arrives and everything rises or falls together, so splitting it this finely is pointless. Synchronized moves belong to the layer of sentiment; research works on the layer of fundamentals. Sentiment can move all four lanes on the same day, yet the anchors of the four lanes are tied to different things — licenses, inventory, R&D, procurement prices. The tide rises and falls together; the rocks beneath never move.
Second objection: this level of detail is beyond ordinary people. The part beyond reach never needs doing. Subsegments one cannot distinguish are simply left alone — the options available will always outnumber the options taken. Telling the four lanes apart does not require becoming an industry expert; it requires knowing which bowl each lane eats from. Four bowls, four words — enough. Classification is the cheapest step of the homework.
Third objection: if you cannot tell them apart, buy a bit of everything — pharma heads up over the long run. What heads up over the long run is the industry, not the price of every purchase. Innovative drugs are overvalued long-term; generics are pinned down by procurement. Long-term holding on the wrong script means playing someone else’s script — in years when the industry rises, the price can still grind a holder out.
The pity is for those who took the wrong script: holding a cyclical’s patience, waiting on a quote that stays overpriced forever.
So the order of questions comes first: ask which bowl it eats from, then talk about how long to hold. Licenses give the floor, inventory gives the rhythm, R&D counsels avoidance, procurement marks the scale of waiting. Four businesses share one sector’s name; they do not share one script. The next time the word pharma comes up, before judging cheap or dear, ask first: which script is it playing? The boundary is drawn as usual: this is a structural read of four business scripts, not investment advice — no stock picks, no price targets. “Avoid the innovative-drug line” is a call about structure, not about timing. Misread the script and you lose; read the script right but the timing wrong, and you lose too.
